Rapt Therapeutics Inc.

05/23/2022 | Press release | Distributed by Public on 05/23/2022 06:06

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis